Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

April 22, 2021 2:38 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a hybrid gene therapy contract manufacturing and clinical stage therapeutic development company, announced today that it will be presenting at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit, being held virtually April 26-27, 2021.

Forge Chief Executive Officer, President, and Co-Founder Timothy J. Miller, Ph.D., will be joined by David Dismuke, Ph.D., the company’s Chief Technical Officer, in a fireside chat format to be moderated by Chardan analyst Gbola Amusa on April 26 at 2:30 p.m. The Forge team will also participate in one-on-one meetings during the conference.

Chardan's 5th Annual Genetic Medicines Manufacturing Summit features leading companies, academics and thought leaders focused on advancing genetic medicines.

“We are honored and grateful to be participating at this exclusive event hosted by Chardan during such an exciting time for Forge Biologics, as we continue to grow our team and our facility with our vision focused sharply on significantly advancing gene therapy manufacturing capabilities,” said Dr. Miller.

The virtual event is limited to current or prospective relationships of Chardan, but Forge’s company presentation video will be available to view after the conference on its website at

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.

Source: Forge Biologics Inc.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Business Wire, Press Releases

Related Entities

Chardan Capital Markets, Gbola Amusa